Sugi Predict

Sugi Predict / Compounds / SCHEMBL2177320

SCHEMBL2177320

SCHEMBL2177320

C=CCO[C@@H]1CN(C(=O)O)[C@](C)(C(=O)N2CCN(c3ccccc3)CC2)[C@@](C)(C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 8/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ MAPT P10636 7/20 0.39
▸ HTT P42858 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ HSD11B1 P28845 1/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173082 0.85 ALDH1A1 (0.46) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL2176908 0.84 ALDH1A1 (0.43) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL4476420 0.83 GPR119 (0.39) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL2173080 0.82 ALDH1A1 (0.44) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL2177052 0.82 LMNA (0.43) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL2173564 0.80 LMNA (0.49) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL2173178 0.80 LMNA (0.49) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL2174529 0.78 ADAM10 (0.39) LMNAALDH1A1
SCHEMBL2174272 0.77 ALOX15 (0.41) LMNAALDH1A1MAPTHTTTSHR
SCHEMBL2174752 0.76 ADAM10 (0.37) LMNAALDH1A1MAPTHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 LMNA 2321/4885ALDH1A1 673/4885MAPT 2590/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 LMNA 2198/4885ALDH1A1 497/4885MAPT 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.